Quizartinib Not Recommended in Europe as Therapy for Relapsed or Refractory AML with FLT3-ITD Mutation
News
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has issued a negative opinion on quizartinib, being developed by Daiichi Sankyo. CHMP ... Read more